Effects of Different Insulin Icodec Initiation Strategies and a Day-4 Supplemental Dosing Decision on Early Fasting Blood Glucose Target Attainment in Type 2 Diabetes: A Multicenter, Randomized, Open-Label, 3x2 Factorial Trial

The goal of this clinical trial is to find the best way to start once-weekly insulin icodec in adults with type 2 diabetes who have not used insulin in the past 3 months, so that their fasting blood glucose reaches the target range within the first week. The main questions it aims to answer are:
* Which of three starting-dose methods brings the most people to their fasting blood glucose target by the end of the first week?
* On day 4 after starting, if fasting blood glucose is still high, does giving one extra half-dose of insulin help more people reach target safely?
Participants will be randomly placed into one of three starting-dose groups: a fixed weekly dose, a dose based on their fasting blood glucose, or a dose based on their body weight. Within each group, participants will also be randomly assigned either to receive an extra insulin dose on day 4 if their fasting blood glucose is at or above a set level, or to receive no extra dose.
Participants will:
* Start once-weekly insulin icodec and continue their current non-insulin diabetes medicines
* Check their fasting blood glucose, including on day 4 after starting
* Wear a blinded continuous glucose monitor during the first 2 weeks and the last 2 weeks
* Attend weekly visits for dose adjustment and safety checks over 12 weeks, followed by a 5-week safety follow-up

Start Date01 Jan 2027

Sponsor / Collaborator

Xi'an International Medical Center Co. Ltd.

NCT07632404

/ Enrolling by invitationNot Applicable

A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Switch From Daily Basal Insulin to Insulin Icodec in People Living With Type 2 Diabetes in Italy

The study will look at how well insulin icodec controls blood sugar levels in participants who have never used it before. Participants with type 2 diabetes (T2D) will be treated with insulin icodec as prescribed to by their doctor, in accordance with usual clinical practice. This study will last for about 22 to 30 weeks.

Start Date28 May 2026

Sponsor / Collaborator

Novo Nordisk A/S

NCT07591519

/ RecruitingPhase 1

Evaluation of the Pharmacokinetics and Pharmacodynamics of IBI3035 and Awiqli? (Ecoporin Insulin Injection) in a Randomized, Open-label, Single-dose, Two-formulation, Crossover Design in Healthy Male Subjects in China: A Phase I Clinical Trial.

This study is a Phase I clinical trial that uses positive glucose clamping technology to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of IBI3035 with insulin injection (Awiqli?) after a single administration in healthy male subjects

Start Date08 May 2026

Sponsor / Collaborator

Innovent Biologics (Suzhou) Co. Ltd.

100 Clinical Results associated with Icodec Insulin

100 Translational Medicine associated with Icodec Insulin

100 Patents (Medical) associated with Icodec Insulin

139

Literatures (Medical) associated with Icodec Insulin

01 Nov 2026·DIABETES OBESITY & METABOLISM

Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin‐Experienced Individuals With Type 2 Diabetes Mellitus: Matching‐Adjusted Indirect Comparisons of QWINT ‐3 Versus ONWARDS 2, and QWINT ‐4 Versus ONWARDS 4

Article

Author: Davidson, Michael B. ; Michaels, Christopher J. ; Tao, Rachel H. ; Redig, Josefine ; Bajaj, Harpreet S. ; Fischer, Marvin ; Pashley, Alex ; Amis, Jess ; Tarafder, Abdul M.

ABSTRACT:

Aims:

To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus.

Methods:

Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 versus ONWARDS 2 (basal‐insulin experienced individuals) and QWINT‐4 versus ONWARDS 4 (basal‐bolus insulin‐experienced individuals).

Results:

In basal insulin‐experienced participants, efsitora was comparable to icodec for change from baseline (CfB) in HbA1c (%) (efficacy estimand mean difference [MD] [95% CI]: 0.137 [−0.058, 0.333]), proportion of participants (PoP) discontinuing treatment due to adverse event (risk difference: −0.0002 [−0.0223, 0.0220]) and CfB in Diabetes Treatment Satisfaction Questionnaire‐Change (DTSQc) (MD: 1.01 [−0.243, 2.27]). Efsitora exhibited significantly reduced weight gain (MD: −1.52 kg [−2.60, −0.447]) and had lower event rates of Level 2 or 3 hypoglycaemia (rate ratio: 0.436 [0.241, 0.786]) versus icodec, despite no significant difference in PoP with Level 2 or 3 hypoglycaemia (odds ratio [OR]: 0.581 [0.294, 1.14]). In basal‐bolus insulin‐experienced participants, efsitora was comparable to icodec: CfB in HbA1c (%) (MD: −0.0447 [−0.252, 0.163]); CfB in body weight (kg) (MD: −0.316 [−1.45, 0.817]); PoP with Level 2 or 3 hypoglycaemia (OR: 1.10 [0.698, 1.73]); event rate of Level 2 or 3 hypoglycaemia (rate ratio [95% CI]: 1.03 [0.759, 1.39]).

Conclusions:

These indirect comparisons suggest that efsitora had lower event rates of hypoglycaemia and less weight gain compared to icodec in basal insulin‐experienced participants. Efsitora was comparable to icodec for all other endpoints.

01 Oct 2026·DIABETES OBESITY & METABOLISM

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

Article

Author: Andersen, Jonas Dahl ; Unnikrishnan, A. G. ; Benamar, Malik ; Rea, Rosangela ; Ponzani, Paola ; Vinther, Siri ; Ji, Linong

ABSTRACT:

Aims:

This post hoc analysis of COMBINE 1–3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once‐weekly combination therapy of basal insulin icodec and semaglutide [a glucagon‐like peptide‐1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.

Materials and Methods:

Treatment outcomes were analysed by trial according to kidney (estimated glomerular filtration rate ≥ 90; 60–< 90; 30–< 60; < 30 mL /min/1.73 m 2 ) and liver (total bilirubin ≤ 21 μmol/L or aspartate aminotransferase [ AST ] ≤ 31/≤ 37 [female/male] U/L; total bilirubin > 21 μmol/L or AST > 31/> 37 [female/male] U/L) function subgroups.

Results:

In COMBINE 1–3, across kidney and liver function subgroups, there were no statistically significant treatment by subgroup interactions for change in glycated haemoglobin (HbA1c) (baseline to week 52), change in body weight (baseline to week 52) or rates of combined clinically significant or severe hypoglycaemia (not assessed by kidney function for COMBINE 2) (all p > 0.05). There were statistically significant treatment by kidney function subgroup interactions for the achievement of HbA1c < 7.0% without weight gain and without clinically significant or severe hypoglycaemia in COMBINE 3 ( p < 0.05) but not COMBINE 1 or 2, and statistically significant treatment by liver function subgroup interactions in COMBINE 1 ( p < 0.05) but not COMBINE 2 or 3. For COMBINE 1 and 3, there were statistically significant treatment by kidney function subgroup interactions for mean weekly total insulin dose, but not statistically significant treatment by liver function subgroup interactions.

Conclusions:

Efficacy and hypoglycaemia outcomes with IcoSema versus comparators were generally consistent among adults with T2D with mild to moderate kidney impairment or impaired liver function.

Trial Registration:

The COMBINE 1–3 trials were sponsored by Novo Nordisk and are registered with ClinicalTrials.gov (NCT05352815; NCT05259033; NCT05013229)

01 Oct 2026·Lancet Diabetes & Endocrinology

Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial

Article

Author: Porcellati, Francesca ; Benamar, Malik ; Wang, Ni ; Watada, Hirotaka ; Pletsch-Borba, Laura ; Ji, Linong ; Mohan, Viswanathan ; Rea, Rosangela R

BACKGROUND:

Stepwise treatment intensification is recommended for managing type 2 diabetes, including insulin initiation when non-insulin glucose-lowering medications are insufficient. Guidelines recommend combining a GLP-1 receptor agonist with basal insulin to improve glycaemic efficacy while reducing weight gain and hypoglycaemia risk. COMBINE 4 evaluated the efficacy and safety of IcoSema, a once-weekly combination therapy of basal insulin icodec and semaglutide (a GLP-1-receptor agonist) versus insulin glargine U100 (glargine U100) in people with type 2 diabetes on oral glucose-lowering medications.

METHODS:

COMBINE 4 was a 40-week, randomised, open-label, treat-to-target, phase 3b trial conducted across 97 sites in nine countries. Adults (aged ≥18 years) with type 2 diabetes (HbA_1c ≥8·0%) receiving oral glucose-lowering medications were randomly allocated in a 1:1 ratio without stratification to IcoSema or once-daily glargine U100. The titration target was 3·9-5·0 mmol/L (70-90 mg/dL). The primary endpoint was change in HbA_1c and the secondary confirmatory endpoint was change in bodyweight, both from baseline to week 40, evaluated in all randomly allocated participants. Adverse events were recorded during weeks 0-45. This trial is registered with ClinicalTrials.gov (NCT06269107) and is complete.

FINDINGS:

Of 653 individuals screened between Feb 15 and Aug 6, 2024, 151 did not meet screening criteria and 17 withdrew before initiating treatment; 243 were randomised to IcoSema and 242 to glargine U100. Of the 485 randomly allocated participants, 286 (59%) were male and 199 (41%) were female, and median age was 58 years (range 26-82). For HbA_1c, from baseline (9·57% for IcoSema and 9·50% for glargine U100), mean change to week 40 was greater with IcoSema versus glargine U100 (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001). From baseline to week 40, mean bodyweight decreased with IcoSema and increased with glargine U100 (-0·79 vs 3·81 kg; ETD -4·61 kg [95% CI -5·46 to -3·75]), confirming superiority of IcoSema (p<0·001). Rate of combined clinically significant (blood glucose <3·0 mmol/L [<54 mg/dL], confirmed with a blood glucose meter) or severe hypoglycaemia (severe cognitive impairment requiring external assistance for recovery) was statistically significantly lower with IcoSema versus glargine U100 (0·29 vs 0·59 episodes per person-year of exposure; estimated rate ratio 0·56 [95% CI 0·32 to 0·97]; p=0·04). Gastrointestinal disorders were the most frequently reported adverse events with IcoSema.

INTERPRETATION:

Once-weekly IcoSema demonstrated superior HbA_1c reduction and bodyweight change, with lower rates of clinically significant or severe hypoglycaemia, versus glargine U100, suggesting that IcoSema might be an effective once-weekly treatment option for insulin-naive individuals with type 2 diabetes inadequately controlled on oral glucose-lowering medications.

FUNDING:

Novo Nordisk.

104

News (Medical) associated with Icodec Insulin

25 Sep 2026

·www.biopharmadive.com

Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

Today, a brief rundown of news involving Novo and Acadia Pharmaceuticals,as well as updates from Nektar Therapeutics, Eli Lilly and Merck & Co.that you may have missed.Novo will pay Swedish biotech Nanexa up to about 1.165 billion euros, or $1.32 billion, for rights to a drug delivery technology capable of making long-acting injectable medicines. Novo intends to use this PharmaShell technology on up to five development programs for obesity, Type 2 diabetes and other cardiometabolic conditions. The partners will work on formulations with different administration-frequency profiles, aiming specifically for medicines that can be dosed as little as once monthly or quarterly. Nanexa will receive 615 million euros in the form of up front payouts and future milestones in the deal. The company formed a similar pact with Moderna last year.Acadia Pharmaceuticalswill keep developing an experimental Alzheimers disease drug despite a setback in testing. According to Acadia, the drug remlifanserin narrowly missed statistical significance in a Phase 2 trial testing its ability to treat hallucinations and delusions in people with Alzheimers disease psychosis. Acadia pointed to the close call, as well as other purported benefits and a favorable safety profile, in deciding to continue enrollment in two ongoing Phase 3 studies.The debate is going to be whether there is still a chance that the drug will succeed in those studies, and in our view there is still a chance, wrote Stifel analyst Paul Matteis. Still, Matteis cautioned that the mid-stage trial was very well-powered and the efficacy findings look quite modest. Shares fell by double digits on Thursday.Nektar Therapeutics has won a legal dispute with development partner Eli Lilly. Nektar sued Lilly in 2023, arguing that the big drugmaker undermined an autoimmune prospect the two collaborated on after purchasing a rival treatment in a company buyout. But while a California federal jury sided with Nektar on Thursday,it awarded the company $90 million, far less than the nearly $1 billion Nektar had been seeking. That verdict is subject to post-trial proceedings, Nektar said in a regulatory filing.The FDA on Thursday approved a once-weekly form of insulin developed by Lilly. To be sold as Onswik, the drug has been cleared for use alongside diet and exercise to improve blood sugar control in people with Type 2 diabetes. In testing, Onswik proved just as effective as commonly used daily shots in keeping blood sugar in check. Onswiks clearance follows the March approval of Novos rival weekly insulin shot Awiqli.U.S. regulators on Thursday also again widened use of Merck & Co.s kidney cancer drug Welireg. Acquired in a 2019 buyout, Welireg had already been cleared in a rare genetic condition, an uncommon adrenal cancer and kidney tumors and generated $470 million in first-half sales. The latest FDA nod involves use in people whose kidney cancer has relapsed after treatment with Keytruda. It comes two months after the agency endorsed Welireg in the adjuvant setting after surgery. '

Drug ApprovalPhase 2Acquisition

24 Sep 2026

·www.biospace.com

Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry

iStock, Tingting Ji The weekly insulin Onswik will now be available to U.S. patients after initial approvals in Europe, Mexico and Japan. Eli Lilly’s weekly insulin, which offers a chance for patients with type 2 diabetes to receive more than 300 fewer injections per year, has been approved in the U.S. The FDA nod sets up yet another market battle between Lilly and obesity rival Novo. Insulin efsitora alfa-gobe will now be known as Onswik after the FDA approval, Lilly said in a Thursday press release . The FDA nod marks the fourth global approval for Onswik, which has already been cleared for use in Europe, Mexico and Japan. Onswik was tested in 3,400 adults in the Phase 3 QWINT clinical trials , which showed non-inferiority to standard once-daily options: insulin glargine, variations of which are sold by several Big Pharmas, or insulin degludec, marketed by Novo as Tresiba. In the QWINT-2 trial, Onswik lowered A1C, a measure of average blood sugar levels, by 1.34%, compared with a 1.26% reduction in patients that took degludec. These results were presented by Lilly at the Annual Meeting of European Association for the Study of Diabetes in September 2024 FDA Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes. August 28, 2026 · 2 min read · Heather McKenzie Read more Lilly promised that Onswik will be made available in the U.S. “in the coming months.” With the approval, Lilly has added another product to compete with Novo, which received FDA clearance for the once-weekly insulin Awiqli in March . The regulatory greenlight followed two FDA rejections in 2024, with the agency objecting to Novo’s request for approval in type 1 diabetes while also raising concerns about the manufacturing process for the drug. Novo refiled the application in September 2025 seeking a type 2 indication. With its approval earlier this year, the drug became the first once-weekly insulin medicine available in the U.S. On Onswik’s new label, Lilly stated that the drug should not be used in patients with type 1 diabetes due to an increased risk of low blood sugar. Awiqli’s label has warnings about using the drug with low blood sugar.

Drug ApprovalPhase 3Clinical Result

16 Sep 2026

·www.novonordisk.com

Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026

Bagsværd, Denmark, 16 September 2026 – Novo Nordisk today announced that new data from its cardiometabolic pipeline and portfolio will be presented at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026 in Milan, Italy, from 28 September to 2 October. The data to be presented at EASD will bring new scientific insights shared across obesity, type 2 diabetes, cardiovascular, kidney and liver-related outcomes. Together, the presentations reflect Novo’s continued focus on advancing understanding and treatment of interconnected cardiometabolic diseases to help many more patients. A total of 44 abstracts will be presented, including data across semaglutide, CagriSema, and zenagamtide. Key presentations will include real-world evidence on Wegovy® pill and CagriSema data exploring appetite regulation, eating behaviour and brain responses to food cues using fMRI (functional Magnetic Resonance Imaging; a non-invasive brain scan that shows which areas of the brain are active during specific tasks or while at rest), and CagriSema data in type 2 diabetes looking at body composition, organ-level fat and bone remodelling mechanisms. Additional presentations include data on semaglutide addressing excess liver fat in people with obesity, and real-world evidence comparing major adverse cardiovascular events in adults with type 2 diabetes escalating to semaglutide 2.0 mg versus switching to tirzepatide. "At EASD 2026 we are sharing the breadth and progression of our cardiometabolic portfolio and pipeline, including key insights that show how our science could make a difference in the everyday lives of people living with obesity, diabetes and related diseases,” said Martin Holst Lange, executive vice president of Research & Development and chief scientific officer at Novo. "We are presenting real-world data on Wegovy® pill, new insights into the broader benefits of semaglutide across Wegovy® and Ozempic®, and CagriSema research exploring food noise, brain responses and body composition. Together, these findings have the potential to shape the next generation of cardiometabolic care and reflect our ambition to develop treatments that can help us work towards more meaningful outcomes for patients." Media are invited to listen to an International Press Briefing on Wednesday, 30 September 2026, during EASD in Milan. The event will be accessible via a webcast on the Novo website, sign up via this link: Novo Nordisk: EASD International Press Briefing, 30 September 2026 (Virtual only) Summary of presentations Accepted data at the 62 nd Annual Meeting of the EASD include the following oral presentations and short oral discussions. Accepted abstracts include preliminary data that may be subject to change in the final published manuscripts. Dates and times of the presentations can be found on the EASD website. Select Novo abstracts to be presented at EASD’s 2026 Scientific Sessions: EASD Scientific symposium: Novo oral presentations and short oral discussions: CagriSema (diabetes and obesity) Cagrilintide Zenagamtide (diabetes) Wegovy® (injection and tablets) Ozempic® UBT251 (diabetes and obesity): Insulin Icodec IcoSema About semaglutide Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of the naturally occurring hormone GLP-1, which regulates blood sugar and body weight. Semaglutide has been tested in several robust clinical development programmes and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases. Semaglutide is marketed under the brand names Wegovy® (injection or tablet), Ozempic® (injection or tablet) and Rybelsus® (tablet). About CagriSema CagriSema is being investigated by Novo as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide. About Fatty liver disease Fatty liver disease - also known as MASH (metabolic dysfunction-associated steatohepatitis) - is a common condition in which excess fat builds up in the liver. Over time, this can cause inflammation and liver damage, especially in people with obesity, type 2 diabetes or other metabolic health conditions. The disease can range from mild fat buildup to more serious forms that may lead to scarring and reduced liver function. About zenagamtide Zenagamtide, formerly known as amycretin, is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo to provide a treatment for adults with overweight or obesity (AMAZE programme) and as a treatment for adults with type 2 diabetes (AMBITION programme). Zenagamtide is under investigation for oral and subcutaneous administration. About type 2 diabetes Type 2 diabetes is a chronic condition that affects how the body processes blood sugar (glucose) for energy. 589 million adults (20-79 years) are living with diabetes – 1 in 9. This number is predicted to rise to 853 million by 2050. Diabetes was responsible for 3.4 million deaths in 2024 – 1 every 9 seconds. About obesity Obesity is a serious, chronic, progressive, and complex disease that requires long-term management. One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off. Obesity is influenced by a variety of factors, including genetics, social determinants of health and the environment. Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram , LinkedIn , TikTok , Facebook , X and YouTube . Contacts for further information

100 Deals associated with Icodec Insulin

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	Canada	Novo Nordisk Canada, Inc.	12 Mar 2024
Diabetes Mellitus, Type 2	Canada	Novo Nordisk Canada, Inc.	12 Mar 2024
Diabetes Mellitus	Switzerland	Novo Nordisk A/S	07 Mar 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes, Gestational	Phase 3	United States	Novo Nordisk Pharma Ltd.	26 Apr 2022
Diabetes, Gestational	Phase 3	China	Novo Nordisk Pharma Ltd.	26 Apr 2022
Diabetes, Gestational	Phase 3	Japan	Novo Nordisk Pharma Ltd.	26 Apr 2022
Diabetes, Gestational	Phase 3	Australia	Novo Nordisk Pharma Ltd.	26 Apr 2022
Diabetes, Gestational	Phase 3	Belgium	Novo Nordisk Pharma Ltd.	26 Apr 2022
Diabetes, Gestational	Phase 3	Bulgaria	Novo Nordisk Pharma Ltd.	26 Apr 2022
Diabetes, Gestational	Phase 3	Croatia	Novo Nordisk Pharma Ltd.	26 Apr 2022
Diabetes, Gestational	Phase 3	Finland	Novo Nordisk Pharma Ltd.	26 Apr 2022
Diabetes, Gestational	Phase 3	India	Novo Nordisk Pharma Ltd.	26 Apr 2022
Diabetes, Gestational	Phase 3	Italy	Novo Nordisk Pharma Ltd.	26 Apr 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ONWARDS 10 (EASD2026)	Phase 3	Diabetes Mellitus, Type 2	382	icodec	vjeqwjjgim(nsqckemsfp) = csbodcmwio kmrqqpdesd (twdphlqkqc ) View more	Positive	28 Sep 2026
ONWARDS 10 (EASD2026)	Phase 3	Diabetes Mellitus, Type 2	382	glargine U100	vjeqwjjgim(nsqckemsfp) = rfwepfvpkz kmrqqpdesd (twdphlqkqc ) View more	Positive	28 Sep 2026
NCT06340854 (ONWARDS 10, CTgov)	Phase 3	Diabetes Mellitus, Type 2	412	Insulin glargine+Insulin icodec	ukxtpvoayz(shbhfaeccw) = ixdmrhzyih temnyyfdfu (xuettqwcbj, 0.83) View more	-	02 Jul 2026
NCT05813912 (ONWARDS 8, Pubmed \| Diabetes Obes Metab)	Phase 3	Diabetes Mellitus, Type 2	148	once-weekly insulin icodec + once-weekly semaglutide	iwbdszpiym(aedzmcrwir) = uijpdsnhfm zpawodeygq (cjfhzdtqpw )	Positive	01 Jul 2026
NCT06288412 (Pubmed \| Diabetes Obes Metab)	Phase 3	Diabetes Mellitus, Type 2	30	Once-weekly basal insulin icodec	zajxlnudkq(dgvujdrrne) = tazmjtwlih mvyolhaibw (fbilzjtitr ) View more	Positive	01 Jul 2026
ADA2026	Not Applicable	Diabetes Mellitus, Type 2	66	Insulin Icodec + Semaglutide (Uncontrolled Type 2 Diabetes)	eamsggmfar(civcqjajbo) = improved significantly from 54.8±23.3% at baseline to 78.1±18.9% (95% CI 9.5-25.5, P<0.001) lfbruyjgfl (ydbwemxodl ) View more	Positive	20 Jun 2026
NCT05813912 (ONWARDS 8, CTgov)	Phase 3	Diabetes Mellitus, Type 2	148	Semaglutide+Insulin Icodec	poqehkfcuh(iryvbdkgbm) = bvdhcrrfer veuaujskje (sdfhrmmskm, 0.86) View more	-	03 Jun 2026
NCT06340854 (ONWARDS 10, Pubmed \| Diabetes Obes Metab)	Phase 3	-	412	once-weekly insulin icodec	xpyebkdpcm(xhxyvkbqor) = ocaruxxgru gqvydmvyfg (kgeheomltv ) View more	Positive	21 May 2026
NCT06340854 (ONWARDS 10, Pubmed \| Diabetes Obes Metab)	Phase 3	-	412	once-daily insulin glargine U100	xpyebkdpcm(xhxyvkbqor) = sbfkdnvyei gqvydmvyfg (kgeheomltv ) View more	Positive	21 May 2026
NCT05823948 (ONWARDS 9, CTgov)	Phase 3	Diabetes Mellitus, Type 2	51	Insulin Icodec	dmkothzzax(ihetgkxlaf) = ctnuwaxftb umsvxjpefi (sbgqixrzzt, 0.91) View more	-	30 Apr 2026
NCT04848480 (ONWARDS 6, Pubmed \| Diabetes Technol Ther)	Phase 3	Diabetes Mellitus, Type 1	246	Insulin Icodec	zyhhbeykuu(sfyhstoywz) = Rates of CGM-based clinically significant hypoglycemic episodes (<3.0 mmol/L for ≥15 consecutive min) were statistically significantly higher with icodec than degludec from baseline to week 26 and week 57. tujqrbcjfl (syumalftof ) View more	Positive	01 Dec 2025
NCT04848480 (ONWARDS 6, Pubmed \| Diabetes Technol Ther)	Phase 3	Diabetes Mellitus, Type 1	246	Insulin Degludec		Positive	01 Dec 2025
NCT05435677 (Pubmed \| Diabetes Ther)	Phase 1	Diabetes Mellitus, Type 2	20	IcoSema	getrfvabkm(mdkpcryirx): ratio = 1.04 (90.0% CI, 0.99 - 1.08) View more	Positive	01 Nov 2025
NCT05435677 (Pubmed \| Diabetes Ther)	Phase 1	Diabetes Mellitus, Type 2	20	icodec		Positive	01 Nov 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis